CIK 0001710072 · Large accelerated filer
Edgewise Therapeutics, Inc.
Sign in to watch- Ticker
- EWTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821725586
- Phone
- 720-262-7002
- Business address
- 1715 38TH ST, BOULDER, CO, 80301
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $201,787
- in 1 filing
Net −$201,787. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-17 | Carruthers R Michael Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2023-08-17 | Russell Alan J Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2023-08-17 | Semigran Marc Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +133,333 | 133,333 | ||
| 2023-08-17 | Donovan Joanne M. CMO | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2023-08-17 | KOCH KEVIN President and CEO | Grant or award · Stock Option (Right to Buy) | +600,000 | 600,000 | ||
| 2023-06-22 | Carruthers R Michael Chief Financial Officer | Option exercise | +10,000 | $0.71 | $7K | 29,024 |
| 2023-06-22 | Carruthers R Michael Chief Financial Officer | Option exercise · Stock Options (Right to buy) | −10,000 | 197,122 | ||
| 2023-06-12 | Fox Jonathan C Director | Grant or award · Stock Option (Right to Buy) | +22,123 | 22,123 | ||
| 2023-06-12 | Thompson Peter A. Director | Grant or award · Stock Option (Right to Buy) | +22,123 | 22,123 | ||
| 2023-06-12 | ROOT JONATHAN D Director | Grant or award · Stock Option (Right to Buy) | +22,123 | 22,123 | ||
| 2023-06-12 | Edris Badreddin Director | Grant or award · Stock Option (Right to Buy) | +22,123 | 22,123 | ||
| 2023-06-12 | Brege Laura Director | Grant or award · Stock Option (Right to Buy) | +22,123 | 22,123 | ||
| 2023-05-02 | Derakhshan Behrad Chief Business Officer | Sale | −1,747 | $8.90 | $16K | 7,020 |
| 2023-05-02 | MOORE JOHN R General Counsel | Sale | −1,897 | $8.90 | $17K | 6,565 |
| 2023-05-02 | Carruthers R Michael Chief Financial Officer | Sale | −1,336 | $8.90 | $12K | 16,126 |
| 2023-05-02 | Russell Alan J Chief Scientific Officer | Sale | −1,602 | $8.90 | $14K | 176,191 |
| 2023-05-02 | Donovan Joanne M. CMO | Sale | −3,254 | $8.90 | $29K | 9,960 |
| 2023-05-02 | KOCH KEVIN President and CEO | Sale | −3,203 | $8.90 | $29K | 7,213 |
| 2023-05-01 | Derakhshan Behrad Chief Business Officer | Option exercise | +5,208 | 8,767 | ||
| 2023-05-01 | Derakhshan Behrad Chief Business Officer | Option exercise · Restricted Stock Units | −5,208 | 10,417 |
Page 16 of 26 · 509 trades